SAN DIEGO, May 14, 2015 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today announced that management will be presenting at the UBS Global Healthcare Conference at the Sheraton New York Times Square Hotel in New York City. The presentation is scheduled for Wednesday, May 20th at 12:00pm Eastern time.
About Receptos
Receptos is a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases. The Company’s lead program, ozanimod (formerly RPC1063), is a sphingosine 1-phosphate 1 and 5 receptor small molecule modulator in development for immune indications including relapsing multiple sclerosis and inflammatory bowel disease. Patents supporting RPC1063 were exclusively licensed to Receptos from The Scripps Research Institute (TSRI). The Company is also developing RPC4046, an anti-interleukin-13 (IL-13) antibody for eosinophilic esophagitis (EoE), an allergic/immune-mediated orphan disease.
CONTACT: Media and Investor Contact: Graham K. Cooper Chief Financial Officer, Receptos (858) 652-5708 gcooper@receptos.com
Help employers find you! Check out all the jobs and post your resume.
